Obermatt
See Similar Stocks →

Corcept Therapeutics

NAQ:CORT · US2183521028
PharmaceuticalsMedium

360

20
EV / EBIT1
Price / Owner Earnings5
Owner Earnings Yield12
Dividend Yield1
Price/Sales42
EV / Gross Profit26
Price/Book7
Return on Capital9
Cash Return on Capital25
Return on Equity21
EBIT Margin4
Gross Profitability100
Cash Conversion91
Accruals100
Owner Earnings Margin15
Sales growth75
Profit Growth79
Long-Term EPS Growth4
Owner Earnings Growth5
Reinvestment97
Price momentum43
Debt load77
Refinancing46
Debt Payback100
Liquidity1
Analyst ratings45
Opinion Changes81
Price Target Upside30
Market mood81
Value Creation6/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Corcept Therapeutics doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA
IndustryPharmaceuticals
SizeMedium
TypePublic Company
ExchangeNASDAQCM
Founded1998
Employees693
Websitecorcept.com
ISINUS2183521028
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
DiabetesNeurologyChronic DiseasesEndocrinologyOncologySurgeryBiotechnologyMedicalPharmaceutical

Description

Corcept Therapeutics Incorporated, a commercial-stage company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. T…

Analysis

Hope premium

Corcept Therapeutics Incorporated is priced well ahead of what the underlying numbers justify, a pattern we describe as a hope premium.

On valuation, the picture is expensive. The owner-earnings multiple stands at 184.4×; owner earnings: the cash an owner could take out each year.

Growth is tepid; the safety picture is adequate. The company scores 6/20 on our value-creation score: not creating value. Analysts lean positive.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
57
2023202420252026

All-time high

57

Jun 2026

All-time low

16

Jan 2024

Average rank

31

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
42
7
18
22
Price/Earnings
1
27
19
52
Price/Book
7
9
9
30
Dividend Yield
1
1
1
1
Value (overall)
4
1
1
19

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Corcept Therapeutics with its peers
Eledon Pharmaceuticals
NAQ:ELDN
16
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Rapport Therapeutics
NMQ:RAPP
13
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Harmony Biosciences Holdings
NMQ:HRMY
94
CountryUSA
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
MBX Biosciences
NSQ:MBX
30
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Zoetis
NYQ:ZTS
56
CountryUSA
IndustryPharmaceuticals
SizeX-Large
Full Stock Analysis →
Adicet Bio
NAQ:ACET
26
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →